These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 28987520)

  • 21. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
    Chayama K; Hayes CN
    Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?
    Feld JJ
    Gastroenterology; 2012 May; 142(6):1356-9. PubMed ID: 22537443
    [No Abstract]   [Full Text] [Related]  

  • 23. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
    Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus resistance to the new direct-acting antivirals.
    Esposito I; Trinks J; Soriano V
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
    Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
    Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C.
    Adinolfi LE; Rinaldi L; Marrone A; Giordano M
    Expert Rev Anti Infect Ther; 2018 Aug; 16(8):595-597. PubMed ID: 30047799
    [No Abstract]   [Full Text] [Related]  

  • 28. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly active anti-hepatitis C therapy: seven lessons from HIV.
    Thomas DL
    Antivir Ther; 2012; 17(6 Pt B):1183-8. PubMed ID: 23186629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targets for antiviral therapy of hepatitis C.
    Rupp D; Bartenschlager R
    Semin Liver Dis; 2014 Feb; 34(1):9-21. PubMed ID: 24782254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
    Kawakami Y; Ochi H; Hayes CN; Imamura M; Tsuge M; Nakahara T; Katamura Y; Kohno H; Kohno H; Tsuji K; Takaki S; Mori N; Honda Y; Arataki K; Takahashi S; Kira S; Tamura T; Masuda K; Nakamura T; Kikkawa M; Chayama K
    J Gastroenterol; 2018 Apr; 53(4):548-556. PubMed ID: 28815329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retreatment with peginterferon and ribavirin in chronic hepatitis C.
    Jo YM; Lee SW; Han SY; Baek YH; Kim SY; Kim WJ; Ahn JH; Lee JY
    World J Gastroenterol; 2015 Feb; 21(6):1994-9. PubMed ID: 25684969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.
    Wilson EM; Rosenthal ES; Kattakuzhy S; Tang L; Kottilil S
    Clin Microbiol Rev; 2017 Jan; 30(1):23-42. PubMed ID: 27795306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
    Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Retreatment of hepatitis C virus Patients in whom Direct-Acting Antivirals have Failed.
    López Zúñiga MÁ; Prieto Moreno M; de Jesús S; López Ruz MÁ
    Gastroenterol Hepatol; 2019 Nov; 42(9):558-561. PubMed ID: 31320125
    [No Abstract]   [Full Text] [Related]  

  • 37. Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions.
    Sulkowski M; Wyles D
    Clin Infect Dis; 2021 Nov; 73(9):e3296-e3299. PubMed ID: 32887999
    [No Abstract]   [Full Text] [Related]  

  • 38. [The Catting-edge of Medicine; Anti-viral therapies for chronic hepatitis C].
    Takehara T
    Nihon Naika Gakkai Zasshi; 2016 Jan; 105(1):112-8. PubMed ID: 27266051
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of Hepatitis C: A New Paradigm toward Viral Eradication.
    Squires JE; Balistreri WF
    J Pediatr; 2020 Jun; 221():12-22.e1. PubMed ID: 32446469
    [No Abstract]   [Full Text] [Related]  

  • 40. State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals.
    Kapadia SN; Jeng PJ; Schackman BR; Bao Y
    Clin Infect Dis; 2018 May; 66(10):1618-1620. PubMed ID: 29206910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.